Table 4.
Studies that utilized MSCs in neuropathic treatment.
| MSC Source | Neuropathy Treated | Title of Study | Reference |
|---|---|---|---|
| hUC-MSC | DPN | Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis. | [216] |
| BM-MSC | DPN | The bone marrow-derived mesenchymal stem cells (BMSCs) alleviate diabetic peripheral neuropathy induced by STZ via activating GSK-3β/β-catenin signaling pathway. | [217] |
| ASC | DPN | Treatment with adipose tissue-derived mesenchymal stem cells exerts anti-diabetic effects, improves long-term complications, and attenuates inflammation in type 2 diabetic rats. | [218] |
| hMSC | CIPN | Nasal administration of mesenchymal stem cells prevents accelerated age-related tauopathy after chemotherapy in mice. | [219] |
| BM-MSC | CIPN | Bone marrow-derived mesenchymal stem cells alleviate paclitaxel-induced mechanical allodynia in rats. | [220] |
| MSC | CIPN | Nasal administration of mesenchymal stem cells reverses chemotherapy-induced peripheral neuropathy in mice. | [221] |
| ASC | CIPN | Adipose-derived stem cells decrease pain in rat model of oxaliplatin-induced neuropathy: Role of VEGF-A modulation. | [222] |
| hASC and hUC-MSC | Neuropathic symptoms via partial sciatic nerve ligation | Intravenous administration of human mesenchymal stem cells derived from adipose tissue and umbilical cord improves NP via suppression of neuronal damage and anti-inflammatory actions in rats. | [223] |
| ASC | Peripheral nerve injury repair for NP relief | Role of adipose tissue grafting and adipose-derived stem cells in peripheral nerve surgery. | [194] |